These differences could be attributed to the different expression statuses of the targeted markers in specific tumor models, namely, while adenocarcinoma TS/A lacks the targeted markers CD105 and CD146, melanoma B16F10 expresses both of the markers; therefore, GET of the plasmid encoding either of these markers also has an impact on tumor cells itself, in addition to the antiangiogenic and vascular disrupting effects on endothelial cells in tumor vasculature. This evidence concerns the gene MCAM and adenocarcinoma.